Evidence map›Paper›PMID 29532444›Full record

ArticleNeurotoxicity research2018

Metabolic Enhancer Piracetam Attenuates the Translocation of Mitochondrion-Specific Proteins of Caspase-Independent Pathway, Poly [ADP-Ribose] Polymerase 1 Up-regulation and Oxidative DNA Fragmentation.

Dinesh Kumar Verma, Sonam Gupta, Joyshree Biswas, Neeraj Joshi, K Sivarama Raju, Mu Wahajuddin, Sarika Singh

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Neurotoxicity research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Dinesh Kumar VermaToxicology Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India.
Sonam GuptaToxicology Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India.
Joyshree BiswasToxicology Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India.
Neeraj JoshiDepartment of Biochemistry and Biophysics, Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
K Sivarama RajuPharmacokinetics & Metabolism Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India.
Mu WahajuddinPharmacokinetics & Metabolism Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India.
Sarika SinghToxicology Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India. ssj3010@gmail.com.
Central Drug Research Institute · INUniversity of California, San Francisco · US

Funding

Science and Engineering Research Board EMR/2015/001282
6 · The paper itself

Abstract

Piracetam, a nootropic drug, has been clinically used for decades; however, its mechanism of action still remains enigmatic. The present study was undertaken to evaluate the role of mitochondrion-specific factors of caspase-independent pathway like apoptotic-inducing factor (AIF) and endonuclease-G (endo-G) in piracetam-induced neuroprotection. N2A cells treated with lipopolysaccharide (LPS) exhibited significant cytotoxicity, impaired mitochondrial activity, and reactive oxygen species generation which was significantly attenuated with piracetam co-treatment. Cells co-treated with LPS and piracetam exhibited significant uptake of piracetam in comparison to only piracetam-treated cells as estimated by liquid chromatography-mass spectrometry (LC-MSMS). LPS treatment caused significant translocation of AIF and endonuclease-G in neuronal N2A cells which were significantly attenuated with piracetam co-treatment. Significant over-expression of proinflammatory cytokines was also observed after treatment of LPS to cells which was inhibited with piracetam co-treatment demonstrating its anti-inflammatory property. LPS-treated cells exhibited significant oxidative DNA fragmentation and poly [ADP-ribose] polymerase-1 (PARP-1) up-regulation in nucleus, both of which were attenuated with piracetam treatment. Antioxidant melatonin but not z-VAD offered the inhibited LPS-induced DNA fragmentation indicating the involvement of oxidative DNA fragmentation. Further, we did not observe the altered caspase-3 level after LPS treatment initially while at a later time point, significantly augmented level of caspase-3 was observed which was not inhibited with piracetam treatment. In total, our findings indicate the interference of piracetam in mitochondrion-mediated caspase-independent pathway, as well as its anti-inflammatory and antioxidative properties. Graphical Abstract Graphical abstract indicating the novel interference of metabolic enhancer piracetam (P) in neuronal death mechanisms.

Indexed as

AnimalsAnnexin A5Apoptosis Inducing FactorCaspasesCell Line, TumorCell Nucleus SizeComet AssayCytokinesDNA FragmentationDose-Response Relationship, DrugEndodeoxyribonucleasesGene ExpressionLipopolysaccharidesL-Lactate DehydrogenaseMembrane Potential, MitochondrialMiceAIFM1 protein, mouseAnnexin A5Apoptosis Inducing FactorCaspasesCytokinesEndodeoxyribonucleasesendonuclease GLipopolysaccharidesL-Lactate DehydrogenaseNeuroprotective AgentsPiracetamPoly(ADP-ribose) PolymerasesReactive Oxygen SpeciesRNA, MessengerApoptosis-inducing factor (AIF)DNA fragmentationEndonuclease-GLipopolysaccharidePiracetamPoly (ADP-ribose) polymerase-1 (PARP-1)

Identifiers

PMID29532444
OpenAlexW2789377304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.